Conflict of interest: None.
Immune functional assay for immunosuppressive management in post-transplant malignancy
Article first published online: 14 JUL 2010
© 2010 John Wiley & Sons A/S
Volume 25, Issue 1, pages E32–E37, January/February 2011
How to Cite
Uemura, T., Riley, T. R., Khan, A., Hollenbeak, C., Schreibman, I., Ghahramani, N., Reeves, B., Domen, R. E., Zander, D. S. and Kadry, Z. (2011), Immune functional assay for immunosuppressive management in post-transplant malignancy. Clinical Transplantation, 25: E32–E37. doi: 10.1111/j.1399-0012.2010.01303.x
- Issue published online: 7 FEB 2011
- Article first published online: 14 JUL 2010
- Accepted for publication 12 May 2010
- Cylex ImmuKnow assay;
- de novo malignancy;
Uemura T, Riley TR, Khan A, Hollenbeak C, Schreibman I, Ghahramani N, Reeves B, Domen RE, Zander DS, Kadry Z. Immune functional assay for immunosuppressive management in post-transplant malignancy. Clin Transplant 2011: 25: E32–E37. © 2010 John Wiley & Sons A/S.
Abstract: Immunosuppression management in post-transplant malignancy is challenging because of a lack of objective immunologic assessment tools. The ImmuKnow assay measures the ATP level from CD4 T cells, quantifying cell-mediated immunity and providing an insight into the immune status of transplant recipients. Its potential use in patients with post-transplant de novo malignancy was evaluated. Thirteen adult transplant patients with de novo malignancy were divided into survivors (n = 9) and non-survivors (n = 4) after malignancy treatment. Tacrolimus and the ImmuKnow levels were monitored before, during, and after malignancy treatment. The ImmuKnow level in non-survivors group was significantly lower before and after malignancy treatment compared to survivors group (p = 0.013 and 0.0014 respectively). In survivor group, the ImmuKnow level was significantly decreased during malignancy treatment (p = 0.019) but recovered to the initial level after the treatment. However, in non-survivor group, the ImmuKnow level remained suppressed throughout the observed period despite a reduction in immunosuppressive drug levels. The ImmuKnow assay can be an objective means evaluating immune status of patients with de novo malignancy. The ImmuKnow assay can express the degree of immune suppression induced by chemotherapeutic or radiation therapy and may be a useful tool in optimizing the timing of re-introduction of immunosuppression after malignancy treatment.